Press Releases NovaBay Pharmaceuticals

Equities

NBY

US66987P4090

Market Closed - Nyse Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
3.44 ^USD	-5.68%		-25.43%	-51.82%

09/05	NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/05	Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates	30/05	BU
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms	13/05	BU
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results	10/05	BU
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon	07/05	BU
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024	06/05	AQ
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024	03/05	BU
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales	22/04	BU
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity	20/04	BU
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses	17/04	BU
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results	27/03	BU
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K	26/03	PU
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024	26/03	BU
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023	15/03	AQ
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023	14/03	BU
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	13/03	AQ
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales	30/01	BU
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union through Sonoma's Extensive Distributor Network	10/01	AQ
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network	09/01	BU
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes	06/12	BU
NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results	10/11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NovaBay Pharmaceuticals

Equities

NBY

US66987P4090

Press Releases

Filters